Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar - Part 2
Estimated time to complete activity: 1 hour 30 minutes
Compatible with all modern internet browsers and mobile devices
EDUCATIONAL OBJECTIVES
Understand the burden of PsO and PsA across clinical domains
Review the similarities and differences in pathology in skin and joint (and GI Mucosa) across psoriatic disease
Discuss IL-23 clinical data and the impact across different tissue domains
TARGET AUDIENCE
This activity is designed for qualified rheumatologists of all levels of seniority, and other healthcare professionals involved in treating patients with inflammatory disease.
PROGRAMME OVERVIEW
In this webinar, Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar - Part 2, experts highlight the broad spectrum of disease experienced by patients with psoriatic disease, and the various similarities and differences in pathology in skin and joint across psoriatic arthritis. Focus on IL-23 and the impact of its clinical data across different tissue domains are also discussed, followed by an interactive Q&A session between the audience and our panel of industry experts.
DISCLOSURE OF CONFLICTS OF INTEREST
CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.
Modules
Title | Presenters | Video | Questions |
Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar - Part 2 |
Professor Iain McInnes Associate Professor Laura Coates Professor Christopher Ritchlin Professor Philip Mease |
1 hour 30 minutes |